


EUROPEAN  
MENOPAUSE  
AND  
ANDROPAUSE  
SOCIETY



Gynecological cancer: all cancers are not the same

Margaret Rees

EMAS Executive Director, Oxford, UK

14 May 2020, EMAS School

# All gynecological cancers are not the same

- Worldwide 1.3 million new gynecological cancer cases are diagnosed each year.
- Different types, stages, hormone dependence
- Different treatments: hysterectomy with or without bilateral salpingo-oophorectomy, radiotherapy, chemotherapy, anti-estrogens
- Menopause management needs to be individualized

- Most cancers diagnosed at an early stage (FIGO stage I–II) after menopause and have a good overall prognosis, with a 5-year survival rate of over 85%.
- Treated with TAH/BSO
- MHT is a reasonable option for patients who are at low risk of tumor recurrence eg early stage but evidence limited
- No evidence about higher stage disease
- No studies are available for women with Lynch syndrome, who are also at increased risk of other cancers.

- May be hormone dependent, estrogen and progesterone receptor testing should be undertaken to guide decisions as to whether MHT can be used.
- No data regarding MHT in non-hormone-dependent tumors.
- No data in Smooth uterine muscle tumors of uncertain malignant potential (STUMPs)

- Three major types of ovarian cancer are:
  - **epithelial** accounting for 90% of cases
  - **germ cell** (3%)
  - **sex cord-stromal** (2%)
- Fallopian tube cancer, primary peritoneal cancer and epithelial ovarian cancer are indistinguishable and share the same genomic signature.

- Epithelial cancers five histotypes:
  - high (aggressive)-grade serous carcinoma
  - low-grade serous carcinoma
  - endometrioid carcinoma
  - clear cell carcinoma
  - mucinous carcinoma
- The different histotypes are now considered to be different diseases.

- **Low-grade serous**
- MHT, currently not recommended for low-grade serous cancer of the ovary or peritoneum in advanced disease
- Letrozole, anastrozole, tamoxifen and leuprolide acetate used after primary cytoreductive surgery and platinum-based chemotherapy for stage II to IV low-grade serous carcinoma of the ovary or peritoneum
- **High-grade serous**
- No evidence to inform practice

- MHT, either systemic or topical, does not appear to be associated with harm and does not appear to decrease overall or disease-free survival.
- Regimen (estrogen alone or combined with a progestogen) depends on whether hysterectomy undertaken

- Most common sex cord stromal tumors
- Affect young women
- May secrete sex steroids
- Can recur up to 20 years after diagnosis
- Hormone dependent: recurrence therapy includes aromatase inhibitors
- But no studies with MHT show harm

- Not hormone dependent
- Regimen (estrogen alone or combined with a progestogen) depends on whether hysterectomy performed
- In utero diethylstilbestrol-exposure associated tumors: no evidence regarding MHT use

- European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Rees M, et al. *Maturitas*. 2020;134: 56–61.